SciTech Development Announces the Closing of Oversubscribed $5.5 Million Funding Round to Continue Cancer Clinical Trials

Investor confidence is fueled by remarkable interim clinical trial results for its drug, ST-001 nanoFenretinide™, showing 100% disease control at higher dose levels.

DETROIT, Sept. 24, 2025 /PRNewswire/ -- SciTech Development, Inc., a clinical-stage oncology company advancing its innovative nanotechnology-enabled cancer drug, today announced the successful close of its Convertible Note Round #3 (CNR 3) at $5.5 million. The round, which officially closed on September 5, 2025, surpassed its original $3.0 million target by $2.5 million.

The strong investor response is driven by extraordinary interim results from SciTech's lead drug candidate, ST-001 nanoFenretinide™ (ST-001), which is currently being evaluated in clinical trials for T-cell Non-Hodgkin Lymphoma (T-cell NHL) across nine prestigious cancer centers.

"This has truly been a breakout year for SciTech," said Earle Holsapple, CEO of SciTech Development. "The oversubscription of our CNR 3 underscores the confidence investors place in our science, our market position, and the transformative potential of ST-001. We are deeply grateful to both new and returning investors for their belief in our mission and support as we advance into the next phase of our trials."

Recent Clinical Highlights

• ST-001 has achieved an unprecedented 100% Disease Control Rate at the highest dose levels to date, with all patients demonstrating either stable disease, partial responses, or showing a clear trajectory toward complete responses.
• Several patients have already experienced confirmed partial responses, marking a critical step on the path toward potential complete responses.
• ST-001 nanoFenretinide has demonstrated efficacy in both early- and late-stage cancer patients, reinforcing its broad therapeutic potential.
• Along with this documented clinical activity at therapeutic doses, the trial has confirmed ST-001 safety, validating the strength of the underlying science behind the drug.
• Importantly, most patients report minimal side effects and have chosen to remain in the trial because of the positive impact on their health and quality of life.

"Our new and returning investors are motivated by the exceptional interim trial results we've delivered and the proven strength of our team," said Andrew Stumpf, CFO of SciTech Development. "This investment enables us to continue to advance clinical development in both T-cell NHL and Small Cell Lung Cancer, while building a strong foundation for our future pipeline."

About SciTech Development, Inc.
SciTech Development is a clinical-stage pharmaceutical company committed to advancing the next generation of cancer treatment. Leveraging its proprietary nanotechnology drug-delivery platform, the company has developed ST-001 nanoFenretinide™, a first-in-class drug currently in clinical trials for T-cell Non-Hodgkin Lymphoma. With its patented design and proven potential, ST-001 may be applicable across a broad range of additional cancers, offering hope for more effective and accessible treatment options.

Investor Relations

For more information, contact David Schaffer at [email protected] or visit www.scitechSDP.com

Forward-Looking Statements
This release may contain forward-looking statements, which involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors including clinical trial outcomes, regulatory decisions, competitive developments, and funding availability.

SOURCE SciTech Development, Inc.